Corline Biomedical AB (CLBIO.ST) Research

Corline Biomedical AB is a company dedicated to the creation, production, and distribution of heparin-based solutions. These solutions are specifically engineered to enhance outcomes in kidney transplantation, cellular therapies, and regenerative medicine. At the heart of their product line is the proprietary Corline Heparin Conjugate (CHC) technology, a unique heparin conjugate that can function as a standalone pharmaceutical compound. The company's diverse portfolio includes Renaparin, aimed at treating end-stage renal failure; Cytoparin, a cell therapy designed for patients with type 1 diabetes; the CHC compound itself for addressing soft tissue injuries; and a variety of medical devices, such as CHS, a coronary stent. Established in 1991, Corline Biomedical AB operates from its headquarters in Uppsala, Sweden.

Market snapshot

Symbol
CLBIO.ST
Price
$17.75
Day change
-0.84%
Market cap
$463.9M
P/E ratio
-31.27x
52-week range
9.96-27.2
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Ascelia Pharma AB (publ) (ACE.ST)
  • Bactiguard Holding AB (publ) (BACTI-B.ST)
  • Bio-Works Technologies AB (publ) (BIOWKS.ST)
  • Elicera Therapeutics AB (publ) (ELIC.ST)
  • Enzymatica AB (publ) (ENZY.ST)
  • FluoGuide A/S (FLUO.ST)
  • Mendus AB (publ) (IMMU.ST)
  • Intervacc AB (publ) (IVACC.ST)

Open Corline Biomedical AB (CLBIO.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.